The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of flupirtine-containing medicines and recommended restrictions in their use. The Committee recommended that oral flupirtine medicines and suppositories should only be used to treat acute (short-term) pain in adult more
To use all functions of this page, please activate cookies in your browser.
